Princeton's Legal Action Against Drug Companies for Insulin Price Inflation
Wednesday, 9 September 2026, 21:30
Princeton's Legal Action
In June, Princeton University initiated a lawsuit against major insulin manufacturers and pharmacy benefit managers (PBMs), citing a conspiracy to artificially inflate prices of insulin. This lawsuit underscores the ongoing issues related to drug pricing that many educational institutions and their employees face.
Details of the Allegations
- Princeton alleges that the drug companies rigged pricing structures.
- This action is part of a broader movement toward greater transparency in drug pricing.
- The lawsuit could set a precedent for similar cases in the future.
As insulin prices continue to rise, the financial burden falls heavily on those who depend on this life-saving medication.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.